Cardiovascular Disease Clinical Trial
Official title:
Factors in Susceptibility to Ischemic Heart Disease in Major Depression: Documentation of Insulin Resistance in Patients With Major Depression Utilizing the Hyperinsulinemic Euglycemic Glucose Clamp
Verified date | January 19, 2007 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A series of studies in patients with major depression have consistently demonstrated a
doubling of the mortality rate at any age, independent of suicide. In addition, the relative
risk for clinically significant coronary artery disease in patients with major depression is
also 2 or more in studies that independently controlled for risk factors such as smoking,
hypertension, etc. The principal long-term goals of the CNE include the determination of the
mechanisms that underlie enhanced susceptibility to premature ischemic heart disease in
patients with major depression, documenting the age at which demonstrable pathophysiologic or
predictive changes begin to occur, and charting their rate of progression. Our long-term goal
is to use our understanding of underlying mechanisms to enhance our capacity to predict who
with major depression is most likely to develop premature ischemic heart disease, to
determine what the mechanisms underlying this susceptibility are, and to develop improved
means for treatment and prevention.
Depressed patients are known to manifest a variety of neuroendocrine changes that predispose
to coronary artery disease including hypercortisolism, decreased secretion of growth hormone
and a deficiency of sex steroids. A final common denominator of these neuroendocrine
abnormalities is insulin resistance. Insulin resistance promotes several changes that would
favor hypertension and increased coronary artery disease including increased sodium
retention, increased activity of the sympathetic nervous system, proliferation of vascular
smooth muscle and deposition of highly metabolically active visceral fat. The latter induces
additional risk factors for coronary disease, including dyslipidemia, hypercoagulation, and
enhanced inflammation. It is a matter of public health importance to document the frequency
and severity of insulin resistance in patients with major depression compared to a closely
matched group of healthy controls. To accurately quantify insulin resistance in each patient
and control, we will apply the hyperinsulinemic euglycemic glucose clamp procedure. This is
the gold standard method for measuring the insulin sensitivity since it reflects the direct
human body glucose metabolic response to a known insulin infusion. Moreover, it is essential
to use this technique in patients with major depression as data indicate that other
alternative procedures give unreliable results in the context of hypercortisolism.
Status | Completed |
Enrollment | 160 |
Est. completion date | January 19, 2007 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 55 Years |
Eligibility |
- INCLUSION CRITERIA Adults between the ages of 21 and 55, with or without major depression as diagnosed with The Structured Clinical Interview of Diagnosis (SCID) of the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV), will be recruited. All depressed patients will be included, although we will characterize patients a priori as having a predominantly melancholic, atypical, or mixed symptom pattern. We plan to recruit at least 20 patients in each group. Both currently depressed patients (greater than 14 on the Hamilton Depression Rating Scale) and those with a history of major depression who are clinically recovered will be included. Patients may be taking psychotropic medications for depression at the time of study. Sub-analyses will be done comparing steady-state glucose utilization rates as a function of mood state and medication status. Subjects should not have significant underlying illnesses known to affect insulin sensitivity, and should have a body mass index between 20 and 30 kg/m2. EXCLUSION CRITERIA 1. Pregnancy 2. Existing diabetes mellitus 3. Body mass index less than 20 or greater than 30 kg/ m2 4. Existing cardiovascular diseases and other end organ diseases 5. Existing peripheral vascular disease 6. HIV infection 7. Patients who are on B-blockers, thiazides, and/or glucocorticoids and cannot discontinue these medications. 8. Subjects who are on oral contraceptives need to discontinue the medication for 1-2 days before the clamp study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking. A national perspective. JAMA. 1990 Sep 26;264(12):1541-5. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|